Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Adoptive cell transfers (ACTs) can interact specifically with inflamed tissues, but lack a mechanism for transport through viscous biological barriers such as mucus when administered locally. Further, maintaining cell function is challenging due to the loss of cellular phenotypes in diseased microenvironments. In this work, the use of magnetically controlled helical microrobots is examined to transport macrophages through physiologically representative mucus and maintain functional phenotypes through drug elution for improved cell delivery. Two-photon lithography and sputter coating are used to fabricate helical particles that are embedded with a small molecule drug, dexamethasone, and coated with nickel and titanium. The attachment of macrophages to the helices and the analysis of how the cells influence the trajectories of cell-helix complexes when exposed to a rotating magnetic field are investigated. Additionally, the transport of complexes is compared in aqueous solutions and artificial mucus, noting a nonzero cell-helix complex velocity in the most viscous mucus for potential therapeutic implications. It is found that attached macrophages display no loss of viability after actuation and exhibit directed polarization toward a prescribed anti-inflammatory phenotype due to the sustained release of dexamethasone from the microrobots. This system provides a proof-of-concept for using magnetically controlled ACTs to enhance the treatment of inflammatory diseases.

Download full-text PDF

Source
http://dx.doi.org/10.1002/smll.202505946DOI Listing

Publication Analysis

Top Keywords

adoptive cell
8
cell transfers
8
helical microrobots
8
magnetically controlled
8
transport
4
transport adoptive
4
cell
4
transfers magnetic
4
magnetic helical
4
microrobots adoptive
4

Similar Publications

Chimeric antigen receptor T-cell (CAR-T) therapies have demonstrated clinical efficacy in treating haematological malignancies, resulting in multiple regulatory approvals. However, there is a need for robust manufacturing platforms and the use of GMP-aligned reagents to meet the clinical and commercial demands. This study investigates the impact of serum/xeno-free medium (SXFM) and cytokine supplementation on CAR-T cell production in static and agitated culture systems, using 24-well plate G-Rex vessels and 500 mL stirred tank bioreactors (STRs), respectively.

View Article and Find Full Text PDF

Memory T cells, a sizable compartment of the mature immune system, enable enhanced responses upon re-infection with the same pathogen. We have recently shown that virus-experienced innate acting T (T) cells can modulate infectious or autoimmune diseases through TCR-independent IFN-γ production. However, how these cells arise remains unclear.

View Article and Find Full Text PDF

Lung Cancer Immunotherapy Approaches: From Clinical Testing to Future Advances.

Adv Pharm Bull

July 2025

Department of Biotechnology and Bioinformatics, North-Eastern Hill University, Shillong, India 793022.

One of the major reason of deaths due to cancer globally is caused by lung cancer of which the two main types include non-small cell and small cell lung cancer. The onset of treatment-resistance in cancer cells offers a serious obstacle to the therapeutic effect despite that primary conventional treatments have provided significant benefits and cures. Cancer immunotherapy offers a compelling alternative in patients by utilizing their immune system to enhance its ability to fight against tumors.

View Article and Find Full Text PDF

Immunometabolism, the intersection of cellular metabolism and immune function, has revolutionized our understanding of T cell biology. Changes in cellular metabolism help guide the development of thymocytes and the transition of T cells from naive to effector, memory and tissue-resident states. Innate-like T cells are a unique group of T cells with special characteristics.

View Article and Find Full Text PDF

Background: Patients with acute myeloid leukemia (AML) are often older, which brings challenges of endurance and persistent efficacy of autologous chimeric antigen receptor (CAR)-T cell therapies. Allogenic CAR-natural killer (NK) cell therapies may offer reduced toxicities and enhanced anti-leukemic potential against AML. CD33 CAR-NK cells have been investigated for AML therapy.

View Article and Find Full Text PDF